LPLexPort

EPPP Psychopharmacology Questions

Psychopharmacology has no domain of its own on Part 1 of the Examination for Professional Practice in Psychology (EPPP); 8 of these 10 questions come from our course’s Biological Bases of Behavior area, a domain ASPPB weights at 10%. Four are about how a drug’s level changes: carbamazepine inducing its own metabolism, ibuprofen slowing lithium’s renal excretion, a five-week fluoxetine washout before phenelzine and seizure risk when alprazolam stops suddenly. The rest are clozapine’s agranulocytosis warning, an alpha-2 agonist for a 10-year-old after early neglect, benzodiazepines in alcohol withdrawal, the CATIE finding on antipsychotic discontinuation, a weight-loss stimulant behind new hallucinations and the training a psychologist needs before prescribing.

Written and reviewed by the LexPort exam-prep team, led by our Founder & Exam-Prep Lead. LexPort builds certification practice questions — this is exam-preparation material, not medical advice. Last reviewed November 2026.

Try 5 EPPP questions

Scored as you go, with every answer explained. No signup.

Question 1 of 5★ 0/5

A 33-year-old female prescribed carbamazepine for acute mania shows excellent initial response, but presents with a re-emergence of manic symptoms three weeks later despite perfect medication adherence. Which pharmacokinetic process best explains this loss of efficacy?

Pick an answer

Test yourself: EPPP Psychopharmacology

Three EPPP practice questions on eppp psychopharmacology — tap an answer for instant feedback. The full simulator has 1,900+, timed and scored.

Question 1

A 42-year-old patient experiences breakthrough bipolar depression while taking a therapeutic dose of lithium. The patient's recent physical exam reveals elevated fasting blood glucose and significant weight gain. Which adjunctive medication recommendation is most appropriate?

▸ Why C is the answer

Lurasidone is an FDA-approved adjunct for bipolar depression that has a highly favorable metabolic profile, making it safe despite the patient's elevated blood glucose. Olanzapine and quetiapine are also effective for bipolar depression but carry significant risks for exacerbating weight gain and metabolic syndrome. Venlafaxine is an antidepressant that risks inducing a manic switch even with lithium on board. Key Takeaway: Lurasidone effectively treats breakthrough bipolar depression while offering a favorable metabolic profile for patients with elevated glucose.

Question 2

A 25-year-old female taking clozapine for schizophrenia is admitted to an inpatient smoke-free facility and within three days develops excessive sedation and drooling. Which pharmacokinetic change most likely accounts for her rapid clinical deterioration?

▸ Why A is the answer

The correct answer is A because hydrocarbons in cigarette smoke act as an inducer of the CYP1A2 enzyme, which metabolizes clozapine. When the 25-year-old female enters an inpatient smoke-free facility, the sudden cessation of smoking removes this induction. This causes clozapine levels to rapidly rise, resulting in excessive sedation and drooling. Option B is incorrect because smoking induces, rather than inhibits, the metabolic enzymes. Option C is incorrect because initiating induction would lower drug levels, which would likely cause psychotic relapse rather than sedation. Option D is incorrect because smoking cessation represents the loss of an inducer, not the initiation of an inhibitor. Psychologists must recognize that abrupt changes in smoking status require immediate medical consultation for therapeutic drug monitoring to prevent dangerous clozapine toxicity. Key Takeaway: Hydrocarbons in cigarette smoke induce CYP1A2; abrupt smoking cessation removes this induction, causing clozapine levels to spike.

Question 3

A 9-year-old girl with ADHD and comorbid Tourette syndrome is prescribed methylphenidate. Two weeks later, her parents report a significant exacerbation of motor tics. The treating psychologist consults with the prescribing pediatrician, noting that this adverse effect is primarily mediated by the medication's specific action in which neural pathway?

▸ Why D is the answer

Methylphenidate blocks the dopamine transporter, leading to increased dopamine availability in the synapse. While its therapeutic effects on attention are mediated by the prefrontal cortex, its action in the nigrostriatal neural pathways can exacerbate motor tics in individuals with Tourette syndrome. Option D correctly identifies this mechanism. Option A is incorrect because methylphenidate increases, not decreases, norepinephrine. Option B is incorrect as serotonin is not the primary neurotransmitter involved in stimulant-induced tic exacerbation. Option C is incorrect because methylphenidate inhibits, rather than enhances, dopamine reuptake. Key Takeaway: Stimulant-induced tic exacerbation is primarily driven by increased dopamine availability in the nigrostriatal pathway.

Question 1

A 33-year-old female prescribed carbamazepine for acute mania shows excellent initial response, but presents with a re-emergence of manic symptoms three weeks later despite perfect medication adherence. Which pharmacokinetic process best explains this loss of efficacy?

  • A) The medication has inhibited its own renal clearance.
  • B) The medication has saturated its plasma protein sites.
  • C) The medication has decreased its own intestinal absorption.
  • D) The medication has induced its own hepatic metabolism.✓
Show rationale

The correct answer is D because carbamazepine is unique among mood stabilizers for causing autoinduction, meaning it stimulates the CYP3A4 enzymes responsible for its own breakdown. Despite perfect medication adherence, the drug is metabolized much faster after a few weeks, leading to subtherapeutic blood levels and the re-emergence of manic symptoms. Option A is incorrect because carbamazepine is metabolized by the liver, not primarily excreted unchanged by the kidneys. Option B is incorrect because saturating protein binding sites would increase the free, active fraction of the drug, leading to toxicity rather than a loss of efficacy. Option C is incorrect because autoinduction affects hepatic processing, not gastrointestinal absorption. Recognizing hepatic autoinduction helps clinicians understand why therapeutic drug monitoring and subsequent dose adjustments are routinely required for this specific anticonvulsant. Key Takeaway: Carbamazepine induces its own hepatic metabolism over time, often requiring dose adjustments to maintain therapeutic blood levels.

Question 2

A 10-year-old child with a history of severe early childhood neglect presents with chronic hyperarousal, impulsivity, and aggressive outbursts. The clinician recommends a medication that acts as an agonist at presynaptic autoreceptors to modulate autonomic tone. How does this agent primarily exert its anxiolytic and calming effects?

  • A) By mimicking GABA to hyperpolarize postsynaptic neurons within the central nervous system pathways.
  • B) By antagonizing postsynaptic dopamine receptors to reduce motor activity and severe behavioral impulsivity.
  • C) By inhibiting norepinephrine release to decrease overall sympathetic nervous system activation and arousal.✓
  • D) By preventing serotonin reuptake to enhance mood stability and promote emotional regulation capacity.
Show rationale

The child exhibits trauma-related hyperarousal, and the prescribed agent is an alpha-2 adrenergic agonist, such as clonidine or guanfacine. These medications bind to presynaptic autoreceptors in the locus coeruleus. When stimulated, these autoreceptors provide negative feedback, signaling the neuron to inhibit norepinephrine release. This reduction in central noradrenergic tone decreases sympathetic arousal, thereby reducing hyperarousal and impulsivity. Option A is incorrect because it describes a direct GABAergic mechanism, whereas alpha-2 agonists target the noradrenergic system. Option B describes the mechanism of antipsychotics, which block dopamine rather than stimulating presynaptic autoreceptors. Option D describes the mechanism of SSRIs, which block reuptake transporters rather than acting as presynaptic agonists to rapidly modulate autonomic tone. Key Takeaway: Alpha-2 adrenergic agonists stimulate presynaptic autoreceptors to inhibit norepinephrine release, effectively reducing central sympathetic hyperarousal.

Question 3

A patient who has been taking high-dose alprazolam for severe anxiety runs out of their prescription and abruptly discontinued the medication three days ago. Based on the pharmacokinetics of this specific agent, which clinical presentation is most likely to occur?

  • A) Severe depressive episode with prominent suicidal ideation and psychomotor retardation.
  • B) Autonomic hyperactivity, severe rebound anxiety, and potential generalized tonic-clonic seizures.✓
  • C) Profound hypersomnolence, bradycardia, and marked respiratory depression requiring intubation.
  • D) Acute extrapyramidal symptoms, including dystonia, akathisia, and severe muscle rigidity.
Show rationale

When a patient who is dependent on a short-acting benzodiazepine like alprazolam suddenly stops taking it, the rapid drop in blood levels triggers severe withdrawal. Option B is correct because withdrawal from CNS depressants causes rebound excitation, leading to autonomic hyperactivity and a high risk of seizures. Option A describes withdrawal from stimulants like cocaine, not depressants. Option C describes symptoms of benzodiazepine intoxication or overdose, not withdrawal. Option D lists extrapyramidal symptoms, which are associated with antipsychotic medications blocking dopamine, not GABAergic withdrawal. Key Takeaway: Abrupt discontinuation of short-acting benzodiazepines carries a high risk of seizures and autonomic hyperactivity.

Question 4

A 68-year-old male stabilized on lithium for bipolar disorder recently begins taking daily ibuprofen for osteoarthritis and subsequently presents to the clinic with tremor and ataxia. Which pharmacokinetic mechanism best explains this clinical presentation?

  • A) Decreased hepatic metabolism of the mood stabilizer
  • B) Reduced renal excretion of the mood stabilizer✓
  • C) Increased volume of distribution for the agent
  • D) Enhanced plasma protein binding of the agent
Show rationale

The correct answer is B because lithium is processed entirely through the kidneys, and NSAIDs like ibuprofen reduce renal clearance, leading to toxic accumulation. This explains the tremor and ataxia in a 68-year-old male who was previously stable. Option A is incorrect because lithium undergoes no hepatic metabolism; it is not processed by the liver. Option C is incorrect because NSAIDs do not increase the volume of distribution for lithium, which is a water-soluble ion. Option D is incorrect because lithium does not bind to plasma proteins, making displacement or enhanced binding impossible. Understanding this renal excretion vulnerability is essential for psychologists collaborating on medical teams, as common over-the-counter pain relievers can quickly precipitate severe lithium toxicity. Key Takeaway: NSAIDs decrease the renal clearance of lithium, rapidly leading to toxic accumulation and neurological symptoms.

Question 5

A 42-year-old female with schizophrenia is starting a new second-generation antipsychotic. Her family is optimistic because she is enrolled in a comprehensive 18-month outpatient program and has no history of substance use. Based on the CATIE trial, what should the psychologist anticipate regarding her medication adherence?

  • A) She has a high probability of discontinuing the medication before the program concludes.✓
  • B) She will likely maintain adherence due to the superior tolerability of second-generation drugs.
  • C) She is expected to discontinue treatment only if she develops severe extrapyramidal symptoms.
  • D) She will probably remain adherent because substance use is the primary discontinuation driver.
Show rationale

A major finding of the CATIE trial was the alarmingly high overall discontinuation rate, with 74 percent of patients stopping their initial medication within 18 months regardless of the specific drug or setting. Therefore, Option A is the most accurate expectation. Option B is incorrect because second-generation drugs did not demonstrate superior tolerability sufficient to prevent widespread discontinuation. Option C is wrong because patients stopped medications for various reasons, including inefficacy, not just extrapyramidal symptoms. Option D is incorrect because while substance use can impact adherence, the primary drivers of discontinuation in the trial were inefficacy and intolerable side effects. Key Takeaway: The CATIE trial highlighted that the majority of patients discontinue their antipsychotic medication within 18 months.

Question 6

A patient with severe alcohol use disorder is admitted to an inpatient detoxification unit. The attending physician prescribes a long-acting benzodiazepine with the primary goal of preventing delirium tremens. Why is this class of medication effective for this specific clinical purpose?

  • A) They block the dopamine reward pathways previously stimulated by chronic alcohol use.
  • B) They directly restore the depleted endogenous opioid peptides caused by alcohol abuse.
  • C) They inhibit the hyperactive serotonergic neurons responsible for severe withdrawal symptoms.
  • D) They exhibit cross-tolerance at the GABA-A receptor to substitute for the missing alcohol.✓
Show rationale

Benzodiazepines are the gold standard for managing alcohol withdrawal because both substances act on the same receptor complex. Option D is correct; benzodiazepines exhibit cross-tolerance at the GABA-A receptor, effectively substituting for alcohol and preventing severe withdrawal symptoms like delirium tremens. Option A is incorrect because blocking dopamine pathways is the mechanism of antipsychotics, not benzodiazepines. Option B is incorrect as it describes opioid pathways, which are targeted by drugs like naltrexone for craving reduction, not acute withdrawal management. Option C is incorrect because serotonin inhibition is not the primary mechanism for treating alcohol withdrawal. Key Takeaway: Benzodiazepines manage alcohol withdrawal effectively due to cross-tolerance at the GABA-A receptor complex.

Question 7

A 38-year-old female with treatment-resistant schizophrenia has failed three prior antipsychotic trials. Her psychiatrist initiates a new medication, but warns her to immediately report sore throat, fever, or signs of infection. Which medication was most likely prescribed and what is the primary risk?

  • A) Risperidone, due to the high risk of hyperprolactinemia.
  • B) Haloperidol, due to the significant risk of tardive dyskinesia.
  • C) Quetiapine, due to the elevated risk of metabolic syndrome.
  • D) Clozapine, due to the severe risk of agranulocytosis.✓
Show rationale

Clozapine is the gold standard for treatment-resistant schizophrenia. The specific warning to report sore throat and fever points to agranulocytosis, a potentially fatal drop in white blood cells. Option A is incorrect because while risperidone causes hyperprolactinemia, it does not require urgent infection warnings. Option B is incorrect because haloperidol causes tardive dyskinesia, not severe immunosuppression. Option C is incorrect because quetiapine causes metabolic issues, not agranulocytosis. Key Takeaway: Clozapine is used for treatment-resistant schizophrenia but requires strict monitoring due to the risk of life-threatening agranulocytosis.

Question 8

A 42-year-old male is discontinuing fluoxetine to begin a trial of phenelzine and is advised by the prescribing physician to maintain a strict five-week washout period. Which pharmacokinetic property dictates this specific timeframe?

  • A) Extensive hepatic autoinduction of the primary medication
  • B) Irreversible receptor antagonism by the initial substance
  • C) Prolonged elimination half-life of the active metabolite✓
  • D) Delayed gastrointestinal absorption of the new compound
Show rationale

The correct answer is C because fluoxetine and its active metabolite, norfluoxetine, have an exceptionally long half-life of up to two weeks. It takes approximately five half-lives to clear a drug, necessitating the five-week washout period before starting an MAOI like phenelzine to prevent fatal serotonin syndrome. Option A is incorrect because fluoxetine is a CYP450 inhibitor, not an autoinducer like carbamazepine. Option B is incorrect because SSRIs perform competitive reuptake inhibition, not irreversible receptor antagonism; the delay is purely due to systemic clearance. Option D is incorrect because the washout period relates to the elimination of the old drug, not the absorption kinetics of the new one. Understanding the elimination half-life of specific psychotropics is vital for anticipating drug-drug interactions during medication transitions. Key Takeaway: Fluoxetine requires a five-week washout before starting an MAOI due to the exceptionally long half-life of its active metabolite.

Question 9

A licensed clinical psychologist practices in a jurisdiction that recently passed prescriptive authority (RxP) legislation. The psychologist holds a 100-hour continuing education certificate in psychopharmacology and has arranged informal supervision with a psychiatrist. They wish to begin prescribing medications for their adult patients with depression. Based on established training standards, what is the required next step for this psychologist?

  • A) Secure a formal collaborative practice agreement with a licensed psychiatric physician.
  • B) Complete an APA-designated postdoctoral training program in advanced clinical psychopharmacology.✓
  • C) Pass the national Psychopharmacology Examination for Psychologists to begin independent prescribing.
  • D) Register with the state medical board for a provisional prescribing license.
Show rationale

To safely and ethically prescribe, psychologists must meet rigorous training standards, which typically involve completing an APA-designated postdoctoral training program (often a master's degree in clinical psychopharmacology) and a formal supervised practicum. Option B is correct because continuing education and informal supervision do not meet the standard for scope expansion. Option A is incorrect; while a collaborative agreement might eventually be needed depending on the state, the foundational training must be completed first. Option C is a necessary later step, but the exam cannot be taken without the prerequisite formal education. Option D is incorrect because provisional licenses are not granted based on informal training. Key Takeaway: Prescriptive authority requires formal postdoctoral training and supervised practicum rather than continuing education.

Question 10

A 48-year-old female with no psychiatric history presents with the sudden onset of visual and tactile hallucinations. Collateral information reveals she recently started taking a newly prescribed stimulant medication for weight loss. Based on these clinical features, the psychologist should:

  • A) Evaluate for a late-onset schizophrenia spectrum.
  • B) Assess for a substance-induced psychotic disorder.✓
  • C) Formulate a primary delusional disorder diagnosis.
  • D) Consider an acute stress psychotic reaction.
Show rationale

You should assess for a substance-induced psychosis because the atypical late age of onset, lack of prior psychiatric history, and prominent visual and tactile hallucinations are classic indicators of medication or substance etiology. Option A is incorrect; while late-onset schizophrenia is possible, the sudden onset tied to a new stimulant makes a primary psychotic disorder much less likely. Option C is incorrect because delusional disorder lacks prominent hallucinations. Option D is incorrect because acute stress reactions do not typically manifest with isolated visual and tactile hallucinations without a severe psychosocial stressor. The atypical symptom presentation points directly to the new medication. Key Takeaway: Visual or tactile hallucinations with late onset strongly indicate a substance-induced psychotic disorder.

1,900+

questions in the simulator

10+ yrs

exam-prep publishing

Free

5 questions · no signup

Built to help you pass faster — by exam-prep publishers with 10+ years' experience and 150,000+ books sold

  • 💡 Key Takeaways — the one transferable rule per question
  • 🔍 Hint highlights — the decisive cue phrases in each stem
  • 📖 Full rationales — why every option is right or wrong

Every EPPP question is written to the current exam outline for quick learning and a clear pass strategy.

EPPP® is a registered mark of the Association of State and Provincial Psychology Boards (ASPPB). ASPPB does not sponsor or endorse LexPort.

EPPP Part 1 Simulator Pro

What the full simulator adds

  • ✓Each explanation works through why the keyed answer holds and where the other choices go wrong, so the concept sticks for the next item
  • ✓None of the 1,923 is an ASPPB exam item; each one is filed under one of the eight Part 1 domains ASPPB uses for exams given in 2026 and 2027
  • ✓Ten tests of 175 questions and one of 173, timed at 198 minutes: the scored-item count at the real 225-item, 4 h 15 min pace. Ours leave out the 50 unscored items and always offer four choices, where real items have three or four
  • ✓A score for each of the eight domains, plus an overall percentage measured against a 70% readiness line we set ourselves; ASPPB reports a scaled 200–800 score and recommends 500 to pass

$29.99 lifetime · or $9.99/month

🛡️ 30-day money-back guarantee · secure PayPal checkout · cancel anytime

10+ years publishing exam-prep books · 150,000+ books soldASPPB EPPP Part 1 exam outline · current for 2026
See what's in the EPPP course

Authoritative sources